Zhu Yusheng
Xian No.1 Hospital;the First Affiliated Hospital of Northwest University;Shaanxi Institute of Ophthalmology, Xian 710002, Shaanxi Province, China; Northwest University, Xian 710069, Shaanxi Province, ChinaWang Tong
Xian No.1 Hospital;the First Affiliated Hospital of Northwest University;Shaanxi Institute of Ophthalmology, Xian 710002, Shaanxi Province, China; Northwest University, Xian 710069, Shaanxi Province, ChinaChen Xiaodong
Xian No.1 Hospital;the First Affiliated Hospital of Northwest University;Shaanxi Institute of Ophthalmology, Xian 710002, Shaanxi Province, China; Northwest University, Xian 710069, Shaanxi Province, ChinaPublic Emergency Special Project of Education Department of Shaanxi Provincial Government(No.20JG033)
Since 2019, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection has been widespread in the world, causing about 770 million infecting and 6.9 million deaths. Vaccines against SARS-CoV-2 infection have become the main way to prevent the severe SARS-CoV-2. The use of SARS-CoV-2 vaccine has substantial protection against the serious consequences of SARS-CoV-2 infection, but multiple systemic adverse reactions can occur after the use of SARS-CoV-2 vaccine. More and more studies have shown that SARS-CoV-2 vaccine caused lesions of ocular conjunctiva, cornea, sclera, uvea, retina and optic nerve tissue and resulted in damage to visual function. In this paper, the classification and characteristics of SARS-CoV-2 vaccines and related studies on ocular tissue lesions were reviewed, hoping to better understand the ocular adverse reactions of SARS-CoV-2 vaccine and provide some theoretical guidance for the prevention and treatment of ocular tissue damage caused by SARS-COV-2 vaccine.
Zhu Yusheng, Wang Tong, Chen Xiaodong. ,/et al.Research progress of SARS-CoV-2 vaccine-related ocular adverse events. Guoji Yanke Zazhi( Int Eye Sci) 2024;24(6):925-929
Copy